Hu X Eric, Kim Nick K, Gray Jeffrey L, Almstead Ji-In K, Seibel William L, Ledoussal Benoit
Procter & Gamble Pharmaceuticals, 8700 Mason-Montgomery Road, Mason, Ohio 45040, USA.
J Med Chem. 2003 Aug 14;46(17):3655-61. doi: 10.1021/jm030272n.
Novel quinolone antibacterial agents bearing (3S)-amino-(4R)-ethylpiperidines were designed by using low energy conformation analysis and synthesized by applying a conventional coupling reaction of the quinolone nuclei with new piperidine side chains. These compounds were tested in MIC assays and found to be highly potent against Gram-positive and Gram-negative organisms. In particular, the new compounds exhibited high activity against the resistant pathogens Staphylococcus aureus (MRCR) and Streptococcus pneumoniae (PR). Importantly, when the (3S)-amino-(4R)-ethylpiperidinyl quinolones were compared with marketed quinolones sharing the same quinolone nuclei but different side chains at the C-7 position, the new quinolones showed superior activity against Gram-positive organisms, including resistant pathogens.
通过低能量构象分析设计了带有(3S)-氨基-(4R)-乙基哌啶的新型喹诺酮抗菌剂,并通过喹诺酮核与新的哌啶侧链的常规偶联反应进行合成。这些化合物在最低抑菌浓度(MIC)测定中进行了测试,发现对革兰氏阳性菌和革兰氏阴性菌具有高效力。特别是,新化合物对耐药病原体金黄色葡萄球菌(MRCR)和肺炎链球菌(PR)表现出高活性。重要的是,当将(3S)-氨基-(4R)-乙基哌啶基喹诺酮与具有相同喹诺酮核但在C-7位具有不同侧链的市售喹诺酮进行比较时,新喹诺酮对包括耐药病原体在内的革兰氏阳性菌显示出优异的活性。